

**South East London Area Prescribing Committee  
Formulary recommendation**

<b>Reference</b>	<b>072</b>
<b>Intervention:</b>	<b>Collagenase (Xiapex®) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity without significant plaque calcification who do not want surgery or have relative contraindications to surgery.</b> (Clostridium collagenase histolyticum is a form of two collagenase enzymes which dissolve penile plaques)
<b>Date of Decision</b>	<b>June 2017</b>
<b>Date of Issue:</b>	<b>July 2017</b>
<b>Recommendation:</b>	<b>Grey – not recommended for prescribing in South East London</b>
<b>Further Information:</b>	<ul style="list-style-type: none"> <li>The South East London Area Prescribing Committee does not recommend the use of collagenase for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30° at the start of therapy.</li> <li>The Committee acknowledged that there was some evidence for the efficacy of this treatment in this indication however it was felt that this was not a high commissioning priority in South East London considering the prevalence and potential significant financial impact.</li> </ul>
<b>Shared Care/Transfer of care document required:</b>	N/A
<b>Cost Impact for agreed patient group:</b>	N/A
<b>Usage Monitoring &amp; Impact Assessment:</b>	<b>Trusts</b> – monitor non-formulary requests and provide data to the APC upon request
	<b>CCGs</b> Monitor monthly high cost drugs data submitted by Trusts and IFRs received for this drug.

<p><b>Evidence reviewed</b></p>	<p><b>References (extracted from evidence evaluation)</b></p> <ol style="list-style-type: none"> <li>1. Honig S. Intralesional collagenase in the treatment of Peyronie's disease. Therapeutic Advances in Urology 2014; 6(2):47-53</li> <li>2. The British Association of Urological Surgeons (BAUS). Peyronie's Disease: Frequently Asked Questions. March 2014. Available via <a href="http://www.baus.org.uk">www.baus.org.uk</a> &lt;Accessed March 15&gt;</li> <li>3. Sherer BA, Warrior K, Levine LA. Updates in peyronie's disease management. Currrent Urology Reports 2014; 15(12):459.</li> <li>4. UKMi Medicines Q&amp;A 407.2. What oral treatments are effective at treating Peyronies disease? Available via <a href="http://www.evidence.nhs.uk">www.evidence.nhs.uk</a> &lt;Accessed March 15&gt;</li> <li>5. Gelbard M, Goldstein I, Hellstrom W.J.G et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronies disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190(1):199-207.</li> <li>6. Summary of Product Characteristics (Xiapex 0.9 mg powder and solvent for solution for injection). Swedish Orphan Biovitrum Ltd. Date of Revision of Text 24.4.15. Available from <a href="http://www.medicines.org.uk">www.medicines.org.uk</a> &lt;Accessed April 15&gt;</li> <li>7. Data on File from Swedish Orphan Biovitrum, Ltd. Xiapex (collagenase clostridium histolyticum) for the treatment of Peyronie's disease - formulary pack. Provided April 15.</li> <li>8. NIHR Horizon Scanning Centre. Collagenase Clostridium histolyticum (Xiapex) for Peyronie's disease - first line (NIHR HSC ID:4823). November 2014. Available from <a href="http://www.hsc.nihr.ac.uk">www.hsc.nihr.ac.uk</a> &lt;Accessed April 15&gt;</li> <li>9. Extracorporeal shockwave therapy for Peyronie's disease. NICE interventional procedure guidance 2003 [IPG29]. National Institute for Clinical Excellence (NICE). Available from <a href="http://www.nice.org.uk">www.nice.org.uk</a> &lt;Accessed April 2015&gt;</li> <li>10. Summary of Product Characteristics (Potaba Capsules). Glenwood, GmbH. Date of Revision of Text 20.10.10. Available from <a href="http://www.medicines.org.uk">www.medicines.org.uk</a> &lt;Accessed May 15&gt;</li> <li>11. Hatzimouratidis K, Eardley I, Giuliano, F et al. Guidelines on penile curvature. February 2012. European Association of Urology (EAU). Available via <a href="http://www.uroweb.org/guidelines/">www.uroweb.org/guidelines/</a> &lt;Accessed April 15&gt;</li> <li>12. Levine LA, Cuzin B, Stephen M et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease; a phase 3 open label study. The Journal of Sexual Medicine 2015; 12(1):248-258.</li> <li>13. Gelbard M, Lipshultz LI, Tursi J et al. Phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronies disease. J Urol 2012; 187(6):2268-2274.</li> <li>14. Jain S et al. Letter to Editor RE: Clinical efficacy safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronies in 2 large double-blind, randomised, placebo controlled phase 3 studies. J Urol 2013; 190: 199-207</li> <li>15. Levine LA, Larsen S. M. Surgical correction of persistent Peyronies Disease following collagenase clostridium histolyticum treatment. Journal of Sexual Medicine 2015; 12:259-264.</li> <li>16. Rojo MAE, Iribarren IM, Rodriguez JC et al. Experience in the use of collagenase clostridium histolyticum in the management of Peyronies disease: current data and future prospects. Therapeutic Advances in Urology 2014; 6(5):192-7.</li> </ol>
---------------------------------	--

**NOTES:**

- a) Area Prescribing Committee recommendations and minutes are available publicly on member CCG websites.
- b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.
- c) **Not to be used for commercial or marketing purposes. Strictly for use within the NHS.**